Core Viewpoint - Luyuan Pharmaceutical (002788.SZ) is focusing on innovation and the cultivation of new technologies and models, with products in the fields of electrocardiograms and fetal heart monitoring having received medical device registration certification and initiated sales [1] Group 1 - The company emphasizes strengthening innovation leadership and focusing on practical implementation [1] - Self-developed products in the electrocardiogram and fetal heart monitoring sectors have been certified and are now in the sales phase [1] - The sales revenue from these products is currently small and has a limited impact on the company's overall performance [1] Group 2 - There are risks and challenges associated with the market expansion of these products, which investors should be aware of [1]

Group 1 - The company is focusing on innovation and is nurturing new technologies and models with potential in the AI application field [2] - The company has developed products in the fields of electrocardiograms and fetal heart monitoring, which have received medical device registration certification and have begun sales [2] - The sales revenue from these products is relatively small and has a minor impact on the company's overall performance [2] Group 2 - The company acknowledges that there are risks and challenges in the market expansion of these products, advising investors to be cautious and invest rationally [2]

2024年报显示，鹭燕医药旗下拥有三家人工智能研究单位，包括从事医药研发的厦门市新一代启智人工 智能产业技术促进中心，以及从事人工智能研究的福建省康源图像智能研究院和广州市康源图像智能研 究院。 产品方面，鹭燕医药自主研发的心电、胎心等领域的人工智能辅助诊断产品已取得医疗器械注册认证， 并启动渠道销售。此外，公司利用图像识别、深度学习等人工智能技术，正在研发一款AI心脏超声图 像辅助诊断系统。截至去年末仍未完成研发，预计对公司未来发展暂无重大影响。 公开资料显示，鹭燕医药主营医药分销与零售业务，主要产品是药品、中药饮片、医疗器械等分销及医 药零售连锁。财报显示，今年前三季度鹭燕医药增收不增利，营收为158.55亿元，同比增长2.7%；归母 净利润为2.2亿元，同比下降14.64%。 12月31日，大牛股鹭燕医药（002788.SZ）盘中跳水，1分钟直线跌停，截至午间收盘，报21.18元/股， 成交金额超13亿元，换手率超15%。 值得注意的是，今年以来，该股股价已涨超160%，其中12月份斩获"五连板"，月内涨超110%。三季报 显示，截至9月30日，鹭燕医药股东人数为2.27万户，较今年6月底的2.35万户 ...

Core Viewpoint - 康泰医学 held an investor relations meeting on September 15, 2025, to discuss product development and market strategies, revealing significant insights into their operations and future plans [1] Group 1: Product Development - The "Embodied Motion Rehabilitation Intelligent Equipment" project, led by Hebei University of Technology in collaboration with Fudan University and Yanshan University, won the first prize in the 2024 Hebei Provincial Science and Technology Progress Award, indicating successful technology transfer into business applications [1] - The company is focusing on the development of mid-to-high-end products and medical devices to address product homogenization and meet changing market demands [1] - The company is actively working on the development of exoskeleton robot products and will disclose relevant information as per regulatory requirements [1] Group 2: Market Strategy - 康泰医学 is enhancing its domestic market presence through deep collaborations with leading e-commerce platforms to boost brand awareness and influence [1] - The company plans to expand its global market coverage by leveraging research and product advantages, targeting regions such as Southeast Asia, Africa, and South America, driven by the increasing demand for cost-effective medical devices due to global aging and home healthcare trends [1] Group 3: Financial Performance - The company's second-quarter profits were impacted by market conditions, seasonal sales, and increased R&D investments, prompting a focus on market promotion, product structure optimization, and cost control to enhance profitability [1] - Shareholder reductions were attributed to personal funding needs, with the company adhering to regulations and commitments while maintaining normal operations [1] Group 4: AI and Innovation - 康泰医学 is investing in AI technology, exploring its integration with medical devices, and focusing on innovations in patient monitoring through algorithm development, aiming to advance smart healthcare [1]

Group 1: Product Development and Innovation - The company has developed key technologies in "embodied motion rehabilitation intelligent equipment," which won the 2024 Hebei Provincial Science and Technology Progress Award [2] - Ongoing projects include medical endoscopes, in vitro diagnostic products, and dental consumables to meet changing market demands [3] - The company focuses on high-end products and has optimized existing products in ECG, blood pressure, and blood oxygen categories while actively developing new products [2] Group 2: Market Strategy and Expansion - The company is enhancing its domestic market presence through deep cooperation with leading e-commerce platforms to increase brand awareness [4] - Plans to expand into Southeast Asia, Africa, and South America are underway, targeting the growing demand for cost-effective medical devices in these regions [6] - The company aims to improve global market coverage and penetration through localized construction and cross-border e-commerce initiatives [6] Group 3: Financial Performance and Governance - The company's performance in the second quarter was not profitable, with profits primarily from the first quarter; management remains confident in future growth [7] - Shareholder reductions in holdings are attributed to personal financial needs and comply with legal regulations [7] - Recent changes in the supervisory board were part of normal governance optimization and did not involve any collective board incidents [4] Group 4: Technological Advancements - The company is actively investing in AI technology, focusing on integrating AI with medical devices and developing algorithms for patient monitoring [7] - Innovations include multi-mode temperature detection and pulse wave-based respiratory rate calculations, contributing to the advancement of smart healthcare [7]